These transgenic mice carry a rearranged Tcr alpha gene from the pathogenic anti-insulin CD4+ T-cell clone BDC12-4.1.
George Eisenbarth, U of Colorado
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inserted expressed sequence) |
This transgenic strain carries a rearranged Tcr alpha gene from the pathogenic anti-insulin CD4+ T-cell clone BDC12-4.1. Transgenic mice are viable and fertile. When hemizygotes are crossed with Stock No. 006304 NOD.FVB-Tg(TcrbBDC12-4.1)82Gse/GseJ, expression of the BDC12-4.1 T-cell receptor is confirmed by FACS analysis of PBMCs from the double transgenic mice. Double transgenic mice develop insulitis, but spontaneous diabetes does not develop, even in older animals (60 weeks of age), nor can insulin autoantibodies be detected in any age group. Splenocytes from double transgenic mice stimulated with B9-23 peptide produce IFN-gamma, whereas no response is observed in controls. When the congenic NOD double transgenic is combined with a homozygous Rag1tm1Mom mutation (such as in Stock No. 003729), recombination of the endogenous TCR and immunoglobulin genes is prevented. As a result, mature T cells in these mice express only the BDC12-4.1 TCR. In addition, approximately 50% of the double transgenic, Rag1tm1Mom homozygote mice develop diabetes by 30 weeks of age. Histopathology indicates severe insulitis and/or destruction of all insulin-producing cells (Jasinski et al 2006). This Tcr alpha transgenic strain when combined with the Tcr beta strain (Stock No. 006304) is useful for further studying the pathogenesis of insulin autoimmunity and diabetes.
In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
BDC12-4.1 is a pathogenic CD4+ T cell clone derived from NOD pancreatic islets. The TCR specifically recognizes a mouse insulin B chain peptide (amino acids 9-23). The TCR alpha chain from the BDC12-4.1 was subcloned into a TCR cassette and microinjected into FVB embryos. Progeny from Founder Line 10 were backcrossed to NOD for 9 generations. In 2006, The Jackson Laboratory received hemizygous mice at generation N9 and backcrossed them once to NOD/LtJ prior to sibling mating.
Expressed Gene | Tcra, T cell receptor alpha chain, mouse, laboratory |
---|---|
Site of Expression |
Allele Name | transgene insertion 10, Joslin Diabetes Center |
---|---|
Allele Type | Transgenic (Inserted expressed sequence) |
Allele Synonym(s) | alpha10; BDC12.4 TCR alpha10 |
Gene Symbol and Name | Tg(TcraBDC12-4.1)10Jos, transgene insertion 10, Joslin Diabetes Center |
Gene Synonym(s) | |
Promoter | Tcra, T cell receptor alpha chain, mouse, laboratory |
Expressed Gene | Tcra, T cell receptor alpha chain, mouse, laboratory |
Strain of Origin | FVB |
Chromosome | UN |
Molecular Note | The TCR alpha (TRAV5D-4*04/TRAJ53*01) chain from the BDC12-4.1 clone was subcloned into a TCR cassette. |
When using the NOD.Tcra BDC12-4.1 mouse strain in a publication, please cite the originating article(s) and include JAX stock #006303 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(TcraBDC12-4.1)10Jos |
Frozen Mouse Embryo | NOD.FVB-Tg(TcraBDC12-4.1)10Jos/GseJ Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | NOD.FVB-Tg(TcraBDC12-4.1)10Jos/GseJ Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | NOD.FVB-Tg(TcraBDC12-4.1)10Jos/GseJ Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | NOD.FVB-Tg(TcraBDC12-4.1)10Jos/GseJ Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.